Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Targeting the glutamine to pyruvate pathway for treatment of oncogenic Kras-associated cancer

Targeting the glutamine to pyruvate pathway for treatment of oncogenic Kras-associated cancer

US Patent 10837015 · Granted Nov 17, 2020

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

CDCP1 antibodies and antibody drug conjugates2025
Combination therapy for PI3K-associated disease or disorder2025
Targeting chromosomal instability and downstream cytosolic DNA signaling for can2023
Directed differentiation of oligodendrocyte precursor cells to a myelinating cel2022
Methods for treating cancer resistant to ErbB therapeutics2021
Directed differentiation of oligodendrocyte precursor cells to a myelinating cel2020
Directed differentiation of oligodendrocyte precursor cells to a myelinating cel2019
Small molecule inhibitor of 3-phosphoglycerate dehydrogenase and uses thereof2019
Small molecule inhibitor of 3-phosphoglycerate dehydrogenase and uses thereof2019
Compositions and methods for modulating NCOA4-mediated autophagic targeting of f2019
Targeting the glutamine to pyruvate pathway for treatment of oncogenic Kras-asso2018
Targeting the glutamine to pyruvate pathway for treatment of oncogenic Kras-asso2018